The American biotech company said its two-antibody cocktail, REGEN-COV, caused a 100% reduction in symptomatic infection and roughly 50% lower overall rates of infection

Serum Institute of India (SII) has made a collaboration with the University of Oxford and AstraZeneca to manufacture the vaccine. The SII has already manufactured 40 million doses of the vaccine

Tthe researchers in the Storm Chase study believe a Long-Acting AntiBody (LAAB) known as AZD7442, developed by AstraZeneca, may offer immediate and long-term protection to people who have been recently exposed to coronavirus

Rapid antigen detection test directly detects presence or absence of coronavirus antigen in patient's body, generating results in 15-20 minutes; ICMR-approved CIPtest is found to have specificity and sensitivity of 98.09 per cent and up to 75 per cent

The mRNA vaccine candidate -  HGCO19 - is being developed by Pune-based company Gennova, and is supported with seed grant under the Ind-CEPI mission of Department of Biotechnology under Ministry of Science and Technology

The new purchase is part of a US government deal to secure nearly 1 million doses of Lilly's bamlanivimab

A blow-by-blow account of how Indian vaccines are being readied

India Stock Market Highlights Today: Global equities were mostly buoyed today encouraged by news on the development of coronavirus vaccines and more assurance for a transition of power in the US to President-elect Joe Biden

The agency said the antibodies are not authorized for patients who are hospitalized due to COVID-19 or require oxygen therapy due to COVID-19

Cipla will sell these kits across 25 markets in Asia, Middle-East and North Africa, Latin America, EU and Australia

COVAXIN's phase-3 trial at AMU is aimed at checking the safety and effectiveness of the COVID-19 vaccine, jointly developed by the Hyderabad-headquartered Bharat Biotech, National Institute of Virology (NIV) and Indian Council of Medical Research (ICMR)

The Food and Drug Administration (FDA) granted emergency use authorization (EUA) to Eli Lilly & Co's bamlanivimab based on trial data

Researchers made their discovery while developing highly sensitive antibody tests for COVID-19. They compared the blood of COVID-19 patients with that of patients who had not had the disease

Cipla Q2 results: India business grew by 17 per cent YoY and 33 per cent QoQ on the back of strong growth across businesses and continued servicing of patients with COVID-19 portfolio

Zydus today said it has filed an Investigational New Drug (IND) application for 'ZYIL1', an oral drug candidate, that has found to be effective in pre-clinic studies to control inflammation in COVID-19 related diseases

Responding to a complaint by RTI activist Saket Gokhale, the commission said it has found no violation of the provisions of the model code in the issue

Regeneron Pharmaceuticals Inc. said Friday that independent monitors had recommended placing on hold enrollment of the most severely ill patients

Stocks to watch today on October 29: Wipro, Hero MotoCorp, GSK Pharma, SBI, L&T among others are the top stocks to watch out for in Thursday's trading session

Validated and approved by ICMR and the National Institute of Virology (NIV), Pune, Cipla's ELIfast is found to have specificity and sensitivity of 99.33 per cent and 92 per cent, respectively

Speaking to reporters after a meeting with AstraZeneca Managing Director Gagan Singh Bedi, he said the first phase of trials of the vaccine were encouraging